We spent a lot of money but the advice given to us by these consultants was never definitive or convincing. Some of it was just wrong. In the end, the Northfield study failed. My firm's short bet was right but not because some consultant told us what to do. Instead, the Northfield study failed because its drug didn't work, which was clear from prior studies and a good understanding of its mechanism. Having a good knowledge of bio-statistics is helpful in biotech investing, but simpler analyses are often better than more complex models.
Prior clinical data is important. Don't ignore (especially when the data are bad.)
This should go without saying, but the scant phase II data supporting the decision to move Stimuvax into a much larger phase III lung cancer trial was pathetic. Oncothyreon bulls glossed over this red flag because the "phase III trial was taking longer than expected" or because "Merck KGaA knew something." Nope. Bad phase II data leads to phase III data. Investors who ignore this rule lose money.
Big Pharma doeesn't always know best.Oncothyreon bulls believed in Stimuvax because they saw Merck KGaA's involvement as a big credibility booster. Stop thinking that way. Pharmaceutical companies are run by people like you and me, and they make mistakes. In fact, Big Pharma execs make a lot of mistakes. The average investment in R&D results in loss of capital to drug companies. The Stimuvax program is an embarrassment to Merck KGaA and was an awful idea. These things happen, people get fired, companies are restructured and life goes on. Don't be the victim of a large company's afterthoughts. Shkreli has no position in Oncothyreon.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV